𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inactivation of uPA and its receptor uPAR by 3,3′-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration

✍ Scribed by Aamir Ahmad; Dejuan Kong; Sanila H. Sarkar; Zhiwei Wang; Sanjeev Banerjee; Fazlul H. Sarkar


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
514 KB
Volume
107
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

3,3′‐Diindolylmethane (DIM) has been studied for its putative anti‐cancer properties, especially against prostate cancer; however, its exact mechanism of action remains unclear. We recently provided preliminary data suggesting down‐regulation of uPA during B‐DIM (a clinically active DIM)‐induced inhibition of invasion and angiogenesis in prostate cancer cells. Since the expression and activation of uPA plays important role in tumorigenicity, and high endogenous levels of uPA and uPAR are found in advanced metastatic cancers, we investigated their role in B‐DIM‐mediated inhibition of prostate cancer cell growth and motility. Using PC3 cells, we found that B‐DIM treatment as well as the silencing of uPA and uPAR by siRNAs led to the inhibition of cell growth and motility. Conversely, over‐expression of uPA/uPAR in LNCaP and C4‐2B cells resulted in increased cell growth and motility, which was effectively inhibited by B‐DIM. Moreover, we found that uPA as well as uPAR induced the production of VEGF and MMP‐9, and that the down‐regulation of uPA/uPAR by siRNAs or B‐DIM treatment resulted in the inhibition of VEGF and MMP‐9 secretion which could be responsible for the observed inhibition of cell migration. Interestingly, silencing of uPA/uPAR led to decreased sensitivity to B‐DIM indicating important role of uPA/uPAR in B‐DIM‐mediated regulation of prostate cancer cell growth and migration. Our data suggest that chemopreventive and/or therapeutic activity of B‐DIM is in part due to down‐regulation of uPA–uPAR leading to reduced production of VEGF/MMP‐9 which ultimately leads to the inhibition of cell growth and migration of aggressive prostate cancer cells. J. Cell. Biochem. 107: 516–527, 2009. © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Down-regulation of uPA and uPAR by 3,3′-
✍ Aamir Ahmad; Dejuan Kong; Zhiwei Wang; Sanila H. Sarkar; Sanjeev Banerjee; Fazlu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

## Abstract 3,3′‐Diindolylmethane (DIM) is a known anti‐tumor agent against breast and other cancers; however, its exact mechanism of action remains unclear. The urokinase plasminogen activator (uPA) and its receptor (uPAR) system are involved in the degradation of basement membrane and extracellul

Amphiregulin antisense oligonucleotide i
✍ Hitoshi Funatomi; Jun Itakura; Toshiyuki Ishiwata; Ira Pastan; Stewart A. Thomps 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 152 KB 👁 2 views

Human pancreatic cancers overexpress the epidermal growth factor (EGF) receptor (EGFR) and all 5 ligands that bind to this receptor, including amphiregulin. It is not known, however, whether amphiregulin contributes in an autocrine manner to enhance pancreatic cancer cell growth. Therefore, we used